Home » Stocks » CHRS

Coherus BioSciences, Inc. (CHRS)

Stock Price: $15.98 USD 0.15 (0.95%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
Market Cap 1.18B
Revenue (ttm) 475.82M
Net Income (ttm) 132.24M
Shares Out 71.41M
EPS (ttm) 1.62
PE Ratio 9.84
Forward PE 37.31
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $15.98
Previous Close $15.83
Change ($) 0.15
Change (%) 0.95%
Day's Open 15.94
Day's Range 15.88 - 16.48
Day's Volume 1,340,167
52-Week Range 10.86 - 22.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 week ago

Their recent struggles may soon give way to rising market interest and more lucrative returns.

Other stocks mentioned: IRWD, SUPN
GlobeNewsWire - 1 week ago

REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor confe...

Zacks Investment Research - 1 week ago

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 1 week ago

- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 -  - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration...

Zacks Investment Research - 2 weeks ago

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 weeks ago

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
GlobeNewsWire - 2 weeks ago

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA...

GuruFocus - 1 month ago

Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosc...

Other stocks mentioned: ABBV, AMGN, BMY, MRK, RHHBY
GlobeNewsWire - 1 month ago

REDWOOD CITY, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation ...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Bo...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P....

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation...

GlobeNewsWire - 3 months ago

REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation...

Seeking Alpha - 4 months ago

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

Zacks Investment Research - 4 months ago

Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 4 months ago

Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 4 months ago

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
GlobeNewsWire - 4 months ago

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released afte...

Seeking Alpha - 5 months ago

Coherus develops and markets biosimilar versions of blockbuster biologic products.

The Motley Fool - 6 months ago

The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?

Seeking Alpha - 7 months ago

Coherus BioSciences' (CHRS) CEO Denny Lanfear on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 7 months ago

– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –

GlobeNewsWire - 7 months ago

REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Direc...

Zacks Investment Research - 7 months ago

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 7 months ago

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

Other stocks mentioned: BIIB, GEN, LXRX, SLRX
GlobeNewsWire - 7 months ago

REDWOOD CITY, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released a...

The Motley Fool - 9 months ago

The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.

GuruFocus - 9 months ago

One way to increase the chances of finding high-quality investments is to look for fairly priced stocks of companies that have good financial conditions and are expected to improve their net e...

Other stocks mentioned: DECK, OMAB
Seeking Alpha - 9 months ago

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream

Seeking Alpha - 10 months ago

Coherus Biosciences: Worth The Risks

The Motley Fool - 10 months ago

These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.

Other stocks mentioned: DTIL
Zacks Investment Research - 10 months ago

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Other stocks mentioned: BSTC, CBZ, DHT, EURN, ITGR, ROCK
GlobeNewsWire - 10 months ago

REDWOOD CITY, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 agg...

GlobeNewsWire - 10 months ago

REDWOOD CITY, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and o...

GlobeNewsWire - 10 months ago

COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020

Zacks Investment Research - 11 months ago

Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.

Other stocks mentioned: ABBV, BRG, HII, IBP
Zacks Investment Research - 11 months ago

Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 11 months ago

REDWOOD CITY, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020, the compensation...

Seeking Alpha - 11 months ago

Coherus BioSciences: Current Weakness Represents A Buying Opportunity

Zacks Investment Research - 1 year ago

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CCS, LGIH, QGEN, REGN
Seeking Alpha - 1 year ago

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 18, 2020, the compensati...

Zacks Investment Research - 1 year ago

Is (CHRS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...

About CHRS

Coherus BioSciences, Inc., a biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid... [Read more...]

Industry
Biotechnology
IPO Date
Nov 6, 2014
CEO
Dennis Lanfear
Employees
317
Stock Exchange
NASDAQ
Ticker Symbol
CHRS
Full Company Profile

Financial Performance

In 2020, CHRS's revenue was $475.82 million, an increase of 33.63% compared to the previous year's $356.07 million. Earnings were $132.24 million, an increase of 47.21%.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 27.89, which is an increase of 74.53% from the latest price.

Price Target
$27.89
(74.53% upside)
Analyst Consensus: Buy